Riyadh – Mubasher: King Abdullah International Medical Research Center (KAIMRC) entered into a partnership with innovative global healthcare provider Sanofi at the seventh edition of the Future Investment Initiative (FII), aiming to advance clinical research in Saudi Arabia.
Upon the signed memorandum of understanding (MoU), the two sides will cooperate to establish a sustainable disease management ecosystem that is powered by artificial intelligence (AI) and real-world evidence (RWE), especially for rare diseases, oncology, and rare blood disorders.
The partnership also aims to elevate Saudi Arabia’s role in global research and development (R&D) as well as healthcare innovation and promote value-based healthcare for improved patient outcomes, according to a press release.
The two sides will collaborate to advance clinical trials and boost expertise in various fields in line with the Ministry of National Guard Health Affairs’ healthcare transformation objectives.
Executive Director of KAIMRC, Ahmed Alaskar, said: “Our partnership with Sanofi, a leading global pharmaceutical company, will enable us to share scientific and clinical expertise especially in the area of rare diseases, propelling progress towards our national goal of becoming a world leader in biotech research while laying the foundation for a sustainable, future-ready healthcare system.”
It is worth noting that Sanofi has endorsed its commitment to the rare disease community in Saudi Arabia by implementing a full-spectrum patient ecosystem, including home infusion and family screening programmes.
From his side, Jean-Paul Scheuer, MCO Lead and Specialty Care General Manager at Sanofi Greater Gulf, said: “Sanofi has a long history of working with the healthcare community in KSA to accelerate innovation and find solutions to patients’ unmet needs, and we’re proud to reinforce our commitment as a strategic partner to Saudi Vision 2030 with this ambitious joint initiative, which opens new windows for us to contribute to the nation’s healthcare transformation journey.”
In 2022, the healthcare provider initiated the Combined Patient Program, which gave Saudi-based rare disease patients greater control over the management of their condition.
At the three-day FII7 event, a total of 23 entities have been strategic partners for the event, which gathered leaders from across the globe in addition to regional officials and investors.
Meanwhile, FII Institute announced four initiatives that serve three continents to support sustainability and as well as the education sector in low and middle-income countries.
